Introduction
Hepatitis C virus (HCV) infection and its progression to chronic hepatitis C (CHC) is a major cause of chronic liver disease and responsible for a high amount of morbidity and mortality in the world 1 . Injection drug users (IDU's) are at high risk for HCV infection and they will significantly contribute to the patient group with end-stage liver disease (ESLD) in the future 2 .
Opioid maintenance treatment (OMT) is established in the therapy of substance abuse and associated with a reduction in illicit drug use, HIV risk behaviour and drug-related criminal activities 3 . In addition OMT has been shown to be an effective framework for adherence and virological success in HIV treatment 4 5 and preventing tuberculosis in patients with HIV 6 . There is increasing evidence of a similar therapeutic response to CHC treatment in patients on OMT, including patients with active IDU, compared to patients without drug dependence [7] [8] [9] [10] . In light of the latest treatment evidence, effective CHC case finding becomes an important prerequisite to provide HCV care to this high risk population with the potential to prevent a significant number of patients from ESLD.
In Switzerland a policy of low-threshold for OMT access has been promoted since the 1990s in response to the HIV epidemic and the majority of patients are treated by general practitioners (GP) 11 12 . However concerns have been raised about the quality of management as one study indicated that patients treated in specialized centres in Switzerland were more likely to receive screening for HCV compared to GP's 13 which contrasts results from USA, Australia and the United Kingdom [14] [15] [16] . We hypothesized that in Switzerland a GP with a high level of commitment but without a special intervention can achieve CHC assessment rates comparable to specialized centres in opioid addicts (with and without a history of IDU) .
In addition we aimed to assess patient characteristics including duration of OMT which were associated with successful CHC assessment in a primary care setting.
Methods
Retrospective analysis of patients who received opioid maintenance therapy (methadone, buprenorphine or morphine retard) between January 1, 2002 through May 31, 2008. Prior to the OMT patients were asked for their informed consent in an anonymous data analysis thus approval by the local ethic committee was not necessary.
Health care system and patient selection
Addicted patients from a single-handed general practice located in Zurich, Switzerland providing standard medical services in addition to an office-based official OMT for opioid addicted patients. During the study period more than 2500 patients without substance abuse have been treated and OMT has been offered to 492 patients.
Opioid-maintenance treatment
Methadone, buprenorphine and morphine were prescribed. The OMT regimen was based on a computer-assisted drug prescription and delivery system (CDDD) that provides a patient tailored dosage regime within a safety framework allowing the patients to choose dosage within an individualised maximal daily dose 17 . According to the patients day structure dispensing and ingestion was observed on a daily or weekly basis (except on weekends).
Primary outcome measurements
A complete CHC assessment was the primary outcome of the study. The following criteria based on the patient record review defined a successful CHC assessment: 
Assessment of patient characteristics
OMT-related data (i.e. duration, average dose) could be accessed and further processed from CDDD. Demographics, psychiatric co-morbidities (based on clinical grounds), selfdeclared addiction-specific variables (i.e. ever and current IDU, concomitant other drug and alcohol abuse), and social-and occupational characteristics (i.e. housing situation, employement based on a written proof) were assessed by systematic review of patient records.
Statistical analysis
Testing for CHC is not the primary focus during initiation of OMT and adherence to OMT has been shown to stabilise after 3 months of treatment 18 therefore we restricted our analysis on patients who were at least 3 months on opioid substitution.
Shapiro-Wilk test was applied to check for Gaussian distribution of the continuous variables and data are presented as medians and interquartile ranges (IQR) when nonnormally distribution was present. According to the definition of successful CHC assessment above patients were categorized into 2 groups (i.e. successful CHC assessment vs. failed CHC assessment). Non-parametric group comparisons were performed to evaluate differences between patient characteristics. A multiple logistic model was used to assess the independent associations between CHC assessment success and patient characteristics (Stata Vers. 10.0). 
Results

CHC assessment rate and determinants of successful screening
Of the 387 patients 14 patients (3.6%) denied a testing for CHC and missing information about informed screening consent was present in 13 patients (3.4%); therefore the following analysis was restricted to 360 patients. In 327 out of 360 patients (90.8%) on OMT of more than 3 months a successful CHC assessment could be performed. Reasons for unsuccessful CHC assessment (n=33) was a missing HCV antibody screening test in 6 patients, no additional RNA testing in 3 patients with antibody detection and lack of HCV genotyping in 24 patients with CHC.
Group comparisons between patients with successful CHC assessment and patients with failed assessments are presented in Table 2 . Duration of OMT and employability were significantly higher in patients with successful CHC assessment whereas the prevalence of other drug and alcohol misuse, IDU, and unstable psychiatric co-morbidity were significantly higher in patients where CHC assessment failed. The methadone dose did not differ between groups. In a multiple logistic regression analysis including all potential determinants of successful CHC assessment (as presented in 
HCV prevalence and HIV-co-infection
Based on the 327 patients with a successful CHC assessment the screening for HCV antibodies was positive in 136 cases (41.6 %) and in 86 of them (63.2%) a CHC (i.e.
detection of HCV RNA) was present which represents a prevalence of CHC of 26.3%. HCV genotype 1and 3 were most common with 43 (50%) and 34 (39.5%) cases, respectively. HCV genotype 4 was responsible for the remaining 9 cases (9.5%). In 20 out of the 110 patients with HCV infection HIV co-infection was present (18.1%).
Discussion
This study examined patient characteristics in an unselected population at high risk for hepatitis C infection in a single-handed general practice in Switzerland. A complete CHC assessment including determination of HCV-RNA and HCV-genotype depending on the antibody screening test was feasible in the vast majority of patients on OMT. The duration of OMT was independently and positively associated with successful CHC assessment . The observed screening rate of 90.8% compares favourable to the HCV antibody screening rate of 77.9% that was found in a survey of specialized centres offering OMT for opioid addicts in Switzerland 13 but contrasts the significantly lower HCV testing by GP's offering OMT in the aforementioned study (reported test rate 66.2%). Follow-up patients in the specialized centres reported a higher rate of ongoing injection drug use (18.2% for heroin, 19.8% for cocaine) compared to our sample (current IDU 9.8%) supposing that our GP patients were more stable in comparison to patients attending a specialised clinic. However long-term OMT patients (minimum follow-up of 2 years) in a specialised outpatient clinic providing low-threshold substitution in Zurich, Switzerland, showed 3 different patterns of concomitant heroine, cocaine and alcohol abuse in an individual longitudinal analysis 19 . This clinical relevant information cannot be supplied by cross-sectional data only. We can not provide solid information about our patients' selection criteria for choosing the current OMT programme.
Patients experienced institutional and GP settings. This fluctuation rate is well known and representative for the current study area where different intervention programmes exist.
Our results support the hypothesis that in Switzerland the described lower HCV testing by GP's compared to specialized centres is probably a lack of awareness rather than a problem of the health care setting. GP's concerns about adherence to CHC treatment and expected side effects might explain reluctance to address HCV screening. Inadequate selfassessed knowledge by GP's treating opioid addicts and the growing evidence of a safe and effective antiviral CHC treatment in IDU's suggest a lack of education and does not question the role of the GP in HCV-related care in patients on OMT 20 21 . The high rate of complete CHC assessment in our study can not be attributed to a specific intervention program focusing on HCV-related care in general practice but may be explained by the high level of commitment of the attending GP with a special interest in addiction medicine. Besides drugrelated medical and social problems the high prevalence of psychiatric comorbidities is typical for patients on OMT. Patients are often not willing to be referred to other institutions or specialists for further diagnostics and treatments. Providing chronic care (i.e. substitution, treatment of psychiatric comorbidities) in combination of acute somatic care (i.e.
gynecological-and infectious related care) in the same setting reduces adherence-and loss to follow-up problems. We believe that the "holistic" approach which is a main feature of a primary care setting is another reason for the achieved success.
We found an independent and positive association between a successful CHC assessment and the duration of OMT. Thus, a patient spending 34 months (i.e. the median duration of OMT of the study population) on opioid substitution has a nearly 80% (i.e. OR 1.017 34 )
increased chance to be HCV tested compared to a patient just fulfilling the inclusion criteria of minimal 3 months on substitution. OMT has been shown to be associated with increased adherence and virological success in HIV treatment 4 5 and in the successful implementation of chemoprophylaxis for patients at high risk for active tuberculosis 6 . Our results further strengthened OMT as a favourable therapeutic setting expanding its role for HCV-related care.
The doses of substitute treatments were on the lower recommended range. The OMT regimen in our study was based on a computerised dispensing of opioid allowing the patients to choose dosage within an individualised safety maximal daily dose. Thus the observed dosages reflect patients preferences taking into account patients subjectively perceived benefits rather than prescribed dosages by the GP. Lewis and colleagues 16 showed that general practice patients with similar drug using backgrounds were more likely to remain in an opioid substitution treatment after 20 months compared to patients treated in a drug clinic.
In addition mean methadone dose in the GP patients was significantly lower at the end of study compared to the drug clinic patients (i.e. 39 mls vs. 46 mls daily) indicating that the OMT benefit can not only be reduced to a pure dose effect but also pointed out the important role of the setting.
The analysis of the current study was based on data of a single-handed general practice and therefore does not address effectiveness of CHC assessment in the primary care setting as opposed to a specialized clinic and generalization of the results might be questioned.
Nevertheless several reasons indicate that the achieved results might be relevant to a broader primary care setting. 1) Our study population has similar characteristics with regard to age, HCV prevalence, illicit (non-IDU) drug use and psychiatric co-morbidities compared to GP patients in other OMT programmes in Switzerland 12 23 and the UK 16 . 2) We achieved a high eligibility rate of 76.6% (OMT duration of less than 3 months was the only exclusion criteria)
which is an important characteristic in the evaluation of the external validity. 3) Our results have been achieved in a "real world" setting (i.e. no specific intervention focusing on HCVrelated care was implemented). Although based on a single practice experience we believe that due to the high eligibility rate and the representative patient population our study provided evidence that OMT can result in a high rate of successful CHC assessment.in a Swiss GP setting. We are not aware of a study that assessed the specific role of an OMT programme in the context of HCV-related care. Our results are in line with the well-known beneficial role of OMT in HIV-related care in specialized centers thus we suggest that longterm OMT in the context of CHC case finding might be desirable for specialized settings as well.
We conclude that a high rate of CHC assessment in unselected patients on OMT is feasible in a primary care setting in Switzerland. The independent association between OMT duration and successful CHC assessment highlights the important role of opioid substitution as a therapeutic framework to optimize CHC case finding in this high risk population.
Declaration of interest
The authors declare no conflict of interest. (14) 9.7 (3) 0.34 * Maximum sample size 360, patients refusing HCV screening (n=14) and with missing informed consent (n=13) were excluded; differences reflect missing information # group comparisons by Chi-square or Fisher exact as appropriate and Mann-Whitney test; † remained independently associated with succesful HCV screening after controlling for age, sex, psychiatric comorbidity, IDU, drug and alcohol use, employability and housing with an OR (95% CI) of 1.017 (1.002-1.032) (p=0.028)
